Growth Metrics

Novartis Ag (NVS) Cost of Revenue (2016 - 2025)

Novartis Ag's Cost of Revenue history spans 14 years, with the latest figure at $3.3 billion for Q2 2025.

  • On a quarterly basis, Cost of Revenue rose 4.7% to $3.3 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $19.1 billion, a 89.36% increase, with the full-year FY2025 number at $13.7 billion, up 6.8% from a year prior.
  • Cost of Revenue hit $3.3 billion in Q2 2025 for Novartis Ag, down from $6.3 billion in the prior quarter.
  • Over the last five years, Cost of Revenue for NVS hit a ceiling of $8.3 billion in Q2 2023 and a floor of $236.0 million in Q3 2022.
  • Historically, Cost of Revenue has averaged $2.9 billion across 5 years, with a median of $1.7 billion in 2023.
  • Biggest five-year swings in Cost of Revenue: soared 2403.16% in 2023 and later crashed 61.64% in 2024.
  • Tracing NVS's Cost of Revenue over 5 years: stood at $238.0 million in 2021, then grew by 6.3% to $253.0 million in 2022, then skyrocketed by 2403.16% to $6.3 billion in 2023, then fell by 1.01% to $6.3 billion in 2024, then plummeted by 47.01% to $3.3 billion in 2025.
  • Business Quant data shows Cost of Revenue for NVS at $3.3 billion in Q2 2025, $6.3 billion in Q4 2024, and $3.2 billion in Q2 2024.